en · de · es · fr · pt
ipamorelin-notes.peptides6155.com › Blog › �ƒŒ景与受体作用机制 — Explained

�ƒŒ景与受体作用机制 — Explained

By Editorial Desk · published 2026-06-28 · last reviewed 2026-07-26 · Blog

RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.

背景与受体作用机制

Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

在机制层面,ipamorelin 与生长激素促分泌受体 1a 型结合,该受体也介导胃饥饿素的多种效应。受体激活后,细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱,它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到,但人体数据仍然有限。

分析检测与储存稳定性

杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子,其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱,因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件,不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照,但其自身赋值同样需要可追溯来源。

冻干状态下的肽通常比溶液状态更稳定,常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺,速率受 pH、缓冲液种类、离子强度与温度共同影响,碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失,分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程,需与操作条件一并考虑。

对 ipamorelin 的常规表征以反相高效液相色谱测定纯度,检测波长多设为 214 nm,因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱,将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来,可以分别覆盖纯度、身份与序列三个不同层次的信息。

Ipamorelin at a glance

PropertyValueNotes
分子式C38H49N9O5五肽,含非天然氨基酸残基
分子量711.85 g/mol理论值,盐形式可能略有差异
外观白色至类白色粉末冻干粉常见
溶解性易溶于水也可溶于部分极性有机溶剂
储存条件-20°C,干燥避光长期保存通常推荐

Ipamorelin Background and Receptor Selectivity

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Related pages on this site

Background from the literature

Insulin granules are a specific type of granule found in pancreatic beta cells. Insulin granules are secretory granules, which are responsible for the storage and secretion of insulin, a hormone that regulates the concentration of glucose in the bloodstream to maintain homeostasis. The release of insulin by granules is signaled by plasma glucose concentrations and the resultant influx of calcium ions in pancreatic cells, which initiate granule exocytosis. Insulin release is biphastic, as insulin is first released in the primary phase by granules closest to the plasma membrane. In the secondary phase, insulin granules are recruited from reserves deeper in the beta cell for a slower release rate. Insulin granules undergo a significant maturation process. First, precursor proinsulin molecules are synthesized in the endoplasmic reticulum and packaged in the golgi network. Insulin granules bud from the trans golgi network and are further sorted via clathrin-coated vesicle transport. After budding, insulin secretory granules are acidified, activating endoproteases PC1/3 and PC2 to convert proinsulin into insulin. The clatherin coating is released and the insulin secretory granules are transported across the cell via actin filaments and microtubules.

Hormonal imbalance (elevated ratio of estrogen to androgen) during early puberty, either due to decreased androgen production from the adrenals and/or increased conversion of androgens to estrogens, leads to transient gynecomastia in adolescent males. It can occur in up to 65% of adolescents as early as age 10 and peaks at ages 13 and 14. It is self-limited in 75–90% of adolescents. Usually, it resolves spontaneously within 1 to 3 years as pubertal progression increases testosterone levels and causes regression of breast tissue. By age 17, only 10% of adolescent males have persistent gynecomastia.

=== Pulp stones === Pulp stones are calcified masses that occur in the pulp, either in the apical or coronal portions. They are classified according to their structure or location. According to their location, pulp stones can be classed either as free (completely surrounded by pulp), embedded (surrounded by dentine tissue) or adherent (attached to pulp wall continuous with dentine, but not fully enclosed). Depending on the structure, they are either true (dentine lined by odontoblasts), false (formed from degenerating cells that mineralise) or diffuse (more irregular in shape to false stones). The aetiology of pulp stones is little understood. It has been recorded that pulpal calcifications can occur due to:

There are two predominantly used proteomic methods when identifying the structure of a peptide/protein, Top-down proteomics (TDP) and Bottom-up proteomics (BUP). TDP involves taking fractionated venom samples and analysing those peptides/proteins with Liquid chromatography tandem-mass spectrometry (LC-MS/MS). This results in the identification and characterisation of all peptides/proteins present in the initial sample. While BUP consists of fractionating and breaking down the peptides/proteins before analysis (LC-MS/MS) using chemical reduction, alkylating and enzymatic digestion (Typically with trypsin). BUP is more commonly used than TDP as breaking down the samples allows the components to meet the ideal mass range for LC-MS/MS analysis. However, there are disadvantages and limitations with both identification methods. BUP results are prone to protein inference problems as large toxins can be broken down into smaller toxins which are shown in the output, but do not exist naturally within the venom sample. While, TDP is the newer method and is able to fill-in the gaps BUP leaves, TDP needs instruments with high amounts of resolving power (Typically 50,000 or above). Most studies will actually use both methods in parallel to obtain the most accurate results. Furthermore, transcriptomic/genomic methods can be used to create cDNA libraries from the extracted mRNA molecules expressed in the venom glands of a venomous animal. These methods optimise the protein identification process by producing the DNA sequences of all proteins expressed in the venom glands.

Sources: en.wikipedia.org

Reference notes

In 2021, the average annual salary in the private sector was €18,630 for women and €24,640 for men, reflecting a 24.4% gap. This difference is partially attributed to variations in working hours, job types, and the prevalence of part-time work, which accounted for approximately 40% of the wage gap in 2017. When adjusted to full-time equivalents, the average wage gap was 15.5% in 2021, down from 17.5% in 2016. The wage gap tends to increase with age: it was 4.6% at age 25 and rose to 27.5% among those over 60. Differences in working time decrease with age, from 20% under age 25 to 10% between ages 25 and 60. For workers, women earned 14.3% less than men for equivalent hours and worked 23.3% fewer hours. Among employees, women earned 4.7% less for similar hours and had nearly equal working time. The pay gap for equal hours was 16.1% among executives and 12.2% among intermediate professions, with women in these groups also working fewer hours (4.7% and 10.9%, respectively). For equivalent positions and working hours, the wage gap was 4.3%, though occupational segregation—such as differences in sector and employer—affects this figure. In the public sector, the overall gender wage gap was 14%. Among executives, the gap was 23%; among workers, 17%; and among employees, 7%. For full-time salaried positions, the gender wage gap declined from 29.4% in 1976 to 16.3% in 2017. The gap narrowed steadily until 1980, remained largely stable until 2000, and began to decrease again thereafter, though part-time employment among women influenced this trend.

===== Venezuela ===== In May 2023, ahead of a South American summit to which all the presidents of the region were invited, Lula met with Venezuelan president Nicolás Maduro and stated that "you know the narrative that was built against Venezuela, of anti-democracy, of authoritarianism" and "it is in your hands, comrade, to build your narrative and turn this party around so that we can definitively win and Venezuela becomes a sovereign country again where only its people, through a free vote, say who will govern". Chilean president Gabriel Boric and Uruguayan president Luis Lacalle Pou, who were some of the summit attendees, disapproved of Lula's comments.

==== Opioid receptor modulators ==== Buprenorphine depot (Brixadi; Buvidal; CAM-2038; CAM-2048) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders Buprenorphine extended-release (Atrigel buprenorphine; BUP-XR-Indivior; depot buprenorphine; RBP-6000; Sublocade; Subutex prolonged release) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone sublingual (naloxone/buprenorphine; Sai Bo Song; SCH-000484; Suboxone) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Methadone (Zoryon) – μ-opioid receptor agonist – opioid-related disorders Nalmefene (Revex) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid overdose, alcoholism Nalmefene (CPH-101; JF-1; Lu AA36143; nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – alcoholism Nalmefene nasal spray (intranasal nalmefene; Indivior; OPNT-003; Opvee) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Nalorphine (Lethidrone, Nalline) – μ-opioid receptor antagonist, κ-opioid receptor agonist – opioid overdose Naloxone injection (Evzio; naloxone auto injector) – opioid receptor antagonist – opioid-related disorders Naloxone intranasal spray (Rezenopy) – μ-opioid receptor antagonist – opioid-related disorders Naloxone intranasal spray (Kloxxado; naloxone nasal spray) μ-opioid receptor antagonist – opioid-related disorders Naloxone multidose nasal spray (AP-003; Narcan) – μ-opioid receptor antagonist – opioid-related disorders Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – opioid-related disorders Naltrexone controlled-release (Vivitrex; Vivitrol; XL-NTX; XR-NTX; ALKS-6428) – opioid receptor antagonist – alcoholism, opioid-related disorders Naltrexone oral (Nalorex; Nemexin; Revia) – opioid receptor antagonist – alcoholism, opioid-related disorders Other opioids (opioid agonist therapy) (e.g., dihydrocodeinone, extended-release morphine) – μ-opioid receptor agonists – opioid use disorder Tianeptine (Coaxil; Stablon; Tatinol) – μ-opioid receptor agonist, other actions – alcoholism

Sources: en.wikipedia.org

Frequently asked questions

ipamorelin 是天然存在的肽吗?

不是。它属于人工合成的五肽,设计上模拟胃饥饿素受体的部分作用,但不存在于人体天然激素谱中。

它和生长激素释放激素有何区别?

生长激素释放激素通过其专用受体起作用,而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放,但信号通路和下游效应并不相同。

文献中主要研究哪些方面?

研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限,长期结局尚不明确。

为什么纯度检测常用 214 nm?

肽键在 214 nm 附近有较强吸收,适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。

Network